Results 181 to 190 of about 143,834 (286)
N-of-1 investigational study of a novel antisense oligonucleotide drug in CHCHD10-related ALS shows early signs of efficacy. [PDF]
Cousin MA +17 more
europepmc +1 more source
Inverse Diels‐Alder Cycloaddition Reaction was developed for ultrasensitive miR‐21 detection. Based on the enhanced Through‐Bond Energy Transfer and catalytic amplification, it shows a detection limit of 3.58 × 10−18 M and 100 aM–100 nM linear range. It enables high‐contrast cell/tissue imaging and distinguishes lung cancer patients in serum, promising
Yikun Li +10 more
wiley +1 more source
Novel Lipoprotein (a) Therapies: A Comprehensive Review. [PDF]
Ebubechukwu U +3 more
europepmc +1 more source
The mitogenome was transcribed into complete primary polycistrons on both strands. The heteropteran mitochondrial transcription termination factor (HmTTF) functions as a bidirectional attenuator rather than a terminator, and co‐evolution of HmTTF and the binding sites was observed.
Shiwen Xu +6 more
wiley +1 more source
Antisense RNA controls the degradation of phycobilisomes in heterocyst-forming cyanobacteria by a transcriptional interference mechanism. [PDF]
Álvarez-Escribano I +4 more
europepmc +1 more source
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino +5 more
wiley +1 more source
Antisense Oligonucleotides as a Gene-Silencing Strategy Regulating Cytosolic G6PDH in <i>Hordeum vulgare</i>. [PDF]
Aquilone A +3 more
europepmc +1 more source
Chronic Non‐Progressive Neurophysiology in an ALS Patient Treated With Tofersen for 6 Years
Muscle &Nerve, EarlyView.
Ivar Winroth +6 more
wiley +1 more source
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
Targeting <i>EZH2</i> oncogenic splicing: decoding the regulatory network and antisense correction. [PDF]
Islam MR +11 more
europepmc +1 more source

